Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, 4-substituted N-(1,1-dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides were synthesized and evaluated in vitro as potential 5 alpha-reductase inhibitors and antiandrogens.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

This review discusses sexual side effects in men with androgenic alopecia treated with 5-alpha reductase inhibitors and reports no new clinical findings.

This study suggests that 5-alpha reductase inhibitors may reduce invasive cancer features and improve survival in men undergoing radical cystectomy for high-grade urothelial carcinoma, although further research is needed to confirm these findings.

This article examines 5 alpha-reductase inhibitors and their link to persistent sexual dysfunction, but it reports no new clinical findings.

Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This review discusses the established efficacy and safety of finasteride and dutasteride for benign prostatic hyperplasia, their use with alpha adrenergic blockers, and the potential unclear role in cancer prevention.

Finasteride reduces prostate size and symptoms with few side effects.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

This study found that for men with moderate-to-severe LUTS/BPH, 6 months of treatment with tamsulosin plus the hexanic extract of S. repens was as effective as tamsulosin plus a 5-alpha-reductase inhibitor but had better tolerability.

Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.

This review discusses sexual dysfunction as a potential side effect of drugs for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms and reports no new clinical results; it emphasizes the need for methodologically robust studies.

This letter reports no new findings and discusses potential concerns regarding 5-alpha reductase inhibitors on lung function, suggesting a reason for discontinuation during the COVID-19 pandemic.

In this study, the authors reported that dutasteride significantly reduced total remission time for COVID-19 symptoms in men compared to placebo, especially for fatigue and loss of taste or smell.

This study found no significant increase in depression risk associated with taking five-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia, although further studies are needed to confirm these findings.

This abstract reports funding sources for ongoing research and does not present any study results.

This review summarizes the association between 5-alpha reductase inhibitors and depression, discussing potential mechanisms such as neuroactive steroid alterations and neuroinflammation, but reports no new clinical results.

This study found that patients with non-muscle invasive bladder cancer who were treated with 5-alpha reductase inhibitors had lower recurrence rates and higher recurrence-free survival rates compared to untreated patients.

This study found no positive association between the use of 5α-reductase inhibitors and the risk of male breast cancer.

This review examines the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia, noting moderate positive effects without complete cure and the need for further research to understand drug mechanisms and pathogenesis.

This study suggests that finasteride may inhibit the enzyme PNMT, potentially contributing to its sexual and psychological side effects.

This meta-analysis concluded that 5α-reductase inhibitors may increase the risk of mild depression, particularly with dutasteride, in patients treated for benign prostatic hyperplasia and androgenic alopecia.

This study found that Medicare patients with benign prostatic hyperplasia had high adherence to 5-alpha reductase inhibitor therapy, which was associated with a reduced risk of needing surgical intervention.

This study found that Finnish men using 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had improved disease-specific survival compared to non-users, suggesting potential benefits of the treatment.

This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.

This review of legal cases found that 5α-reductase inhibitors, alleged to cause sexual, mental, and physical side effects, have led to numerous lawsuits with increasing litigation expected in the future.

This study explored the optimization of phytochemicals from Alstonia boonei to develop potential 5-alpha reductase inhibitors for Benign Prostatic Hyperplasia, finding promising analogs with enhanced binding affinity and stability compared to Finasteride, warranting further experimental validation.

This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.

This study on rats found that finasteride and dutasteride increased collagen density in penile tissues and caused changes in prostate cells, but did not significantly alter erectile pressures compared to controls.